Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Pharma (IGC) over the last 16 years, with Q3 2025 value amounting to $90.5 million.

  • Pharma's Shares Outstanding (Weighted Average) rose 1901.24% to $90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.5 million, marking a year-over-year increase of 1901.24%. This contributed to the annual value of $76.5 million for FY2025, which is 3004.31% up from last year.
  • According to the latest figures from Q3 2025, Pharma's Shares Outstanding (Weighted Average) is $90.5 million, which was up 1901.24% from $83.0 million recorded in Q2 2025.
  • In the past 5 years, Pharma's Shares Outstanding (Weighted Average) ranged from a high of $90.5 million in Q3 2025 and a low of $42.0 million during Q1 2021
  • Over the past 4 years, Pharma's median Shares Outstanding (Weighted Average) value was $63.7 million (recorded in 2023), while the average stood at $64.9 million.
  • As far as peak fluctuations go, Pharma's Shares Outstanding (Weighted Average) surged by 626.33% in 2021, and later skyrocketed by 3997.35% in 2024.
  • Over the past 4 years, Pharma's Shares Outstanding (Weighted Average) (Quarter) stood at $51.1 million in 2021, then grew by 24.82% to $63.7 million in 2023, then rose by 21.82% to $77.6 million in 2024, then increased by 16.52% to $90.5 million in 2025.
  • Its last three reported values are $90.5 million in Q3 2025, $83.0 million for Q2 2025, and $76.5 million during Q1 2025.